Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIFE: Nal-IRI + 5-FU/LV in Advanced Biliary Tract Cancer
NCT03044587Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jan 2018
- Primary completion
- Jan 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in biliary tract cancer (BTC), sponsored by AIO-Studien. Started Jan 2018; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03044587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044587.